Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

May 14, 2021

Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update

May 10, 2021

Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico

Apr 27, 2021

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 11, 2021

Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

Mar 9, 2021

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 5, 2021

Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

Mar 2, 2021

Cellectar to Present at BIO CEO & Investor Digital Conference

Feb 10, 2021

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 27, 2021

Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 12, 2021
RSS
    • 1...
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • ...36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A